Partnering for Vaccine Emerging Markets—Berlin, June 10–11, 2013

Abstract

Phacilitates 1st Partnering event for Vaccine Emerging Markets brought together approximately 100 attendees from developed and developing world vaccine manufacturers, leading non-profit organizations and industry suppliers. The goal was to discuss the vaccine needs in the developing world and how these needs can be met by leveraging collaboration and partnership models, by improving access to existing, new and next generation vaccines, by using novel technologies to drive competitive advantage and economics of vaccine manufacturing and by investing in localized capacity, including capacity for pandemic vaccines. The present article summarizes insights out of 30 oral contributions on how quality and capacity requirements can be balanced with cost by using novel manufacturing technologies and operating models.

Keywords: :

• vaccines
• economics
• quality
• capacity
• emerging markets
• flexible manufacturing
• single-use

Financial and Competing Interest Disclosure

Annelies Onraedt is the Global Vaccine Market Manager of Pall Corporation, a bioprocess solutions provider. There are no financial interests or conflicts with the subject matter disclosed in this manuscript. No writing support was provided for the production of this manuscript.